FDA draft guidance calls prospective meta-analyses ‘gold standard’

FDA issued draft guidance asking sponsors planning to submit meta-analyses with regulatory applications to take a prospective approach to identifying suspected therapy-related safety signals. The gold standard, the agency said, are analyses planned prior to the start of the

Read the full 399 word article

User Sign In